Rentschler Biopharma, a globally recognized Contract Development and Manufacturing Organization (CDMO), is making significant strides in the biomanufacturing landscape. The company's recent investments showcase its commitment to expanding cGMP capabilities and bolstering cell and gene therapy
Vertex Pharmaceuticals is on the brink of introducing suzetrigine, a cutting-edge non-opioid painkiller that has showcased promising results in recent phase 3 clinical trials. As the battle against opioid addiction and abuse intensifies, the advent of suzetrigine brings hope for a safer approach to
Clinical trials have long faced significant challenges in enrolling and retaining participants, a problem exacerbated by logistical and engagement difficulties inherent in the clinical trial process. Recent data highlights that up to one-third of trial participants drop out before the studies are
The modern biopharmaceutical industry is witnessing a significant transformation, thanks to the integration of artificial intelligence (AI) tools in early drug discovery. AI’s capabilities in managing and analyzing vast amounts of data generated from cell-based preclinical models through imaging a
In a significant leap forward for oncology, the U.S. Food and Drug Administration (FDA) has given the green light to Astellas Pharma Inc.'s VYLOY (zolbetuximab-clzb) for treating adults with advanced, unresectable, or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric
Charles River Laboratories has taken a significant stride in the realm of biopharmaceutical research by launching the Retrogenix Non-Human Protein Library. This innovation is particularly designed to help clients assess the off-target interactions of their therapeutics with non-human proteins. The
